Pfizer Inc.

NYSE:PFE   3:59:59 PM EDT
40.04
-0.07 (-0.18%)
4:29:11 PM EDT: $40.09 +0.05 (+0.13%)
Products

FDA Accepts Supplemental New Drug Application For Pfizer’S Xalkori For The Treatment Of Pediatric Alk-Positive Anaplastic Large Cell Lymphoma

Published: 09/23/2020 11:31 GMT
Pfizer Inc. (PFE) - FDA Accepts Supplemental New Drug Application for Pfizer’s Xalkori® (crizotinib) for the Treatment of Pediatric Alk-positive Anaplastic Large Cell Lymphoma.
Pfizer Inc - Prescription Drug User Fee Act (pdufa) Goal Date for a Decision by FDA is January 2020.